For example, for a patient with a singular, II pathological grades, complete capsule tumor that is 7 cm in diameter, and a series of specific laboratory indices (their median level, i.e., ALB = 41.6 g/L, AFP = 10.9 ng/mL, PT = 13.3 second, and TBIL = 16.2 μmol/L), our model predicts that after the receipt of adjuvant CIK cell immunotherapy, the 3- and 5-year OS rate would significantly increase from 47.9% and 38.4% to 62.2% and 48.8%, respectively. Here, ALB is linked to neoplasm.